Having trouble accessing articles? Reset your cache.

BioCryst reports forodesine data for CTCL

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said once-daily oral forodesine produced an overall response

Read the full 120 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE